Chr. Hansen on Track After Strong Second Quarter

09 Apr 2014 --- Chr. Hansen has experienced a strong second quarter and maintains the outlook for the year. “Following a strong Q2 with 10% organic growth and solid margin development we remain on track to deliver on our outlook for the full year, expecting organic revenue growth of 7-9% and an EBIT margin before special items above 26%,” says CEO Cees de Jong.

“We have continued to implement our Nature’s No. 1 strategy with initiatives to support the future growth and profitability of Chr. Hansen. I am especially pleased with the good performance of both the Cultures & Enzymes Division and the EMEA region in general as well as to see the first sales of cultures for crop protection.”

Highlights first half 2013/14:
•Revenue EUR 353 million, unchanged from first half 2012/13
•Organic growth 6%
•EBIT before special items and impairments EUR 88 million and EBIT margin before special items and impairments 25.0%, both unchanged from last year

Second quarter 2013/14 results:
•Revenue EUR 182 million, up 4% on last year
•Organic growth 10%
•EBIT margin before special items and impairments 24.8%, up from 23.3% last year

Outlook for 2013/14:
The outlook for 2013/14 is unchanged from the announcement of 15 January 2014.

Organic revenue growth is expected to be 7-9%.

The EBIT margin before special items is expected to be above 26%.